INSECTICIDInsecticides (India) Ltd.
Insecticides (India) Q2 FY27 Results: Consolidated Net Profit ₹56.17 Crore on Total Income of ₹685 Crore
- Earnings
- Agro-chemicals
Reviewed byRachit TripathiBlacklitt Research
Insecticides (India) Ltd (NSE: INSECTICID) reported consolidated total income of ₹685.47 crore and net profit of ₹56.17 crore for the quarter ended 30 Sep 2026, it said in a filing on 05 Nov 2026. Standalone total income was ₹679.29 crore and standalone net profit ₹50.58 crore.
Key highlights
Consolidated
Including its subsidiaries
- Total income: ₹685.47 crore, up 7.1% YoY and 11.1% QoQ
- Net profit and EPS: ₹56.17 crore, down 5.0% YoY and up 28.0% QoQ; basic EPS ₹19.30
- Finance costs: ₹6.58 crore, up 58.4% YoY from ₹4.16 crore
Standalone
The company on its own, without its subsidiaries
- Total income: ₹679.29 crore, up 5.5% YoY and 10.1% QoQ
- Net profit and EPS: ₹50.58 crore, down 8.6% YoY and up 20.9% QoQ; basic EPS ₹17.38
- Finance costs: ₹6.41 crore, up 57.2% YoY from ₹4.08 crore
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 685.47 | 640.21 | +7.1% | 616.87 | +11.1% | |
| Revenue from operations | 686.31 | 637.70 | +7.6% | 611.52 | +12.2% |
| Other income | -0.84 | 2.51 | n/a | 5.34 | n/a |
| 56.17 | 59.11 | -5.0% | 43.87 | +28.0% | |
| Profit before tax | 75.36 | 78.86 | -4.4% | 58.82 | +28.1% |
| Finance costs | 6.58 | 4.16 | +58.4% | 4.69 | +40.3% |
| Depreciation | 9.89 | 9.33 | +6.0% | 9.71 | +1.8% |
| Tax expense | 19.19 | 19.75 | -2.8% | 14.95 | +28.4% |
| Net profit margin | 8.19% | 9.23% | -1.04 pp | 7.11% | +1.08 pp |
| EPS, basic (₹) | 19.30 | 20.31 | -5.0% | 15.08 | +28.0% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
The company says it manufactures and distributes agro-chemicals in one business segment, Agro-Chemicals, covering technical and formulation products. The consolidated results include subsidiaries IIL Biologicals Limited and Kaeros Research Limited and the jointly controlled entity OAT & IIL India Laboratories Private Limited.
The joint statutory auditors, S S Kothari Mehta & Co. LLP and Devesh Parekh & Co., issued unmodified limited review reports on both sets of results. Latest quarter (Q1 FY27) consolidated net profit was ₹43.87 crore, down 24.2% YoY.
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 679.29 | 643.92 | +5.5% | 617.11 | +10.1% | |
| Revenue from operations | 680.18 | 641.25 | +6.1% | 616.48 | +10.3% |
| Other income | -0.88 | 2.67 | n/a | 0.62 | n/a |
| 50.58 | 55.31 | -8.6% | 41.83 | +20.9% | |
| Profit before tax | 67.95 | 74.19 | -8.4% | 56.26 | +20.8% |
| Finance costs | 6.41 | 4.08 | +57.2% | 4.65 | +37.8% |
| Depreciation | 9.72 | 9.27 | +4.9% | 9.59 | +1.4% |
| Tax expense | 17.37 | 18.88 | -8.0% | 14.43 | +20.3% |
| Net profit margin | 7.45% | 8.59% | -1.14 pp | 6.78% | +0.67 pp |
| EPS, basic (₹) | 17.38 | 19.01 | -8.6% | 14.38 | +20.9% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone net profit fell 8.6% YoY on total income up 5.5%, and profit before tax fell 8.4% to ₹67.95 crore. The standalone tax charge of ₹17.37 crore is 25.6% of profit before tax, compared with ₹18.88 crore on ₹74.19 crore a year earlier.
Consolidated net profit of ₹56.17 crore is ₹5.59 crore higher than the standalone figure of ₹50.58 crore. Standalone other income was ₹-0.88 crore, and finance costs of ₹6.41 crore are 0.9% of total income.
Inference
The Board declared an interim dividend of ₹5 per equity share, 50% of the ₹10 face value, for financial year 2026-27, with a record date of 12 Nov 2026 and payment on or after 17 Nov 2026, subject to applicable taxes.
The Board approved the appointment of Veera Bhadram Garimella as an Independent Director (Additional) for five years from 5 Nov 2026 to 4 Nov 2031, subject to shareholder approval by postal ballot. The company says the postal ballot details will be communicated in due course.
Not stated: the reason for the rise in finance costs, the reason for the sharp rise in standalone trade receivables, and whether the ESPS offer of 19,393 shares at ₹330 will be taken up in full.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
